<div id="readability-page-1"><p><span>Arcellx (NASDAQ:ACLX - Get Free Report)</span>'s stock had its &#34;neutral&#34; rating reaffirmed by research analysts at Cantor Fitzgerald in a report released on Wednesday,Benzinga reports.</p><p>A number of other equities analysts have also commented on ACLX. Wells Fargo &amp; Company lowered shares of Arcellx from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and set a $115.00 price objective on the stock. in a report on Monday, February 23rd. Canaccord Genuity Group  set a $115.00 price objective on shares of Arcellx in a report on Monday, February 23rd. Evercore  set a $115.00 price objective on shares of Arcellx in a report on Monday, February 23rd. Robert W. Baird  reiterated a &#34;neutral&#34; rating and issued a $115.00 price objective (up from $106.00) on shares of Arcellx in a report on Monday, February 23rd. Finally, UBS Group downgraded shares of Arcellx from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and boosted their target price for the stock from $100.00 to $115.00 in a research report on Tuesday, February 24th. One equities research analyst  has rated the stock with a Strong Buy rating, one  has assigned  a Buy rating, sixteen have assigned  a Hold rating and one  has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of &#34;Hold&#34; and an average price target of $111.87.</p><p><b>View Our Latest Stock Report on ACLX</b></p><h2>Arcellx Stock Performance</h2><p>Shares of NASDAQ:ACLX remained flat at $115.07 during midday trading on Wednesday. 14,666,200 shares of the company traded hands, compared to its average volume of 1,498,960. The firm has a market capitalization of $6.73 billion, a P/E ratio of -28.27 and a beta of 0.25. The firm has a fifty day moving average price of $111.71 and a two-hundred day moving average price of $87.66. Arcellx has a 1-year low of $47.86 and a 1-year high of $115.13. </p><p>Arcellx (NASDAQ:ACLX - Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($1.01) earnings per share for the quarter, meeting the consensus estimate of ($1.01). The business had revenue of $1.65 million for the quarter, compared to analyst estimates of $13.40 million. Arcellx had a negative net margin of 1,027.26% and a negative return on equity of 55.42%.  On average, equities research analysts forecast that  Arcellx will post -2.91 EPS for the current fiscal year. </p><h2>Insider Buying and Selling at Arcellx</h2><p>In related news, insider Rami Elghandour sold 89,916 shares of the business's stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $113.92, for a total transaction of $10,243,230.72. Following the completion of the sale, the insider owned 276,051 shares of the company's stock, valued at $31,447,729.92. This represents a 24.57% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. 8.35% of the stock is currently owned by corporate insiders. </p><h2>Institutional Inflows and Outflows</h2><p>A number of hedge funds and other institutional investors have recently bought and sold shares of ACLX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in  Arcellx by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,753 shares of the company's stock valued at $1,893,000 after purchasing an additional 1,390 shares during the period.  Empowered Funds LLC acquired a new position in  Arcellx during the 1st quarter valued at about $1,768,000.  Intech Investment Management LLC boosted its stake in  Arcellx by 27.7% during the 1st quarter. Intech Investment Management LLC now owns 21,967 shares of the company's stock valued at $1,441,000 after purchasing an additional 4,760 shares during the period.  Prudential Financial Inc. boosted its stake in  Arcellx by 49.2% during the 2nd quarter. Prudential Financial Inc. now owns 4,900 shares of the company's stock valued at $323,000 after purchasing an additional 1,615 shares during the period.  Finally, Norges Bank acquired a new position in  Arcellx during the 2nd quarter valued at about $739,000. 96.03% of the stock is owned by institutional investors and hedge funds. </p><h2>About Arcellx</h2> (Get Free Report)<p>Arcellx, Inc <span>NASDAQ: ACLX<span></span></span> is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company's proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.  </p><p>The company's pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Arcellx</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNMWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNMWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Arcellx Right Now?</h2><p>Before you consider Arcellx, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcellx wasn't on the list.</p><p>While Arcellx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ACLX

<p>Cantor Fitzgerald has reiterated a "neutral" rating on Arcellx (NASDAQ: ACLX) shares. Other analysts have also weighed in, with Wells Fargo downgrading the stock to "equal weight" and setting a price target of $115. Canaccord Genuity and Evercore also set the same price target. The stock is currently trading at $115.07, with an average rating of "Hold" and a price target of $111.87. Arcellx reported earnings of ($1.01) per share, meeting estimates, with revenue of $1.65 million, significantly below expectations. Insider Rami Elghandour sold shares, reducing his stake by 24.57%.</p>

Arcellx's (ACLX) "Neutral" Rating Reiterated at Cantor Fitzgerald